Effects of Tacrolimus and Other Immune Targeting Compounds on Binge-Like Ethanol Drinking in High Drinking in the Dark Mice

Kolter B. Grigsby, Antonia M. Savarese, Pamela Metten, Barbara J. Mason, Yuri A. Blednov, John C. Crabbe, Angela R. Ozburn

Research output: Contribution to journalArticlepeer-review

Abstract

High Drinking in the Dark (HDID-1) mice represent a unique genetic risk model of binge-like drinking and a novel means of screening potential pharmacotherapies to treat alcohol use disorders (AUDs). We tested the effects of tacrolimus (0, 0.5, 1, and 2 mg/kg), sirolimus (0, 5, 10, and 20 mg/kg), palmitoylethanolamide (PEA; 0, 75, 150, and 225 mg/kg), and secukinumab (0, 5, 20, and 60 mg/kg) on binge-like ethanol intake (2-day, “Drinking in the Dark” [DID]) and blood alcohol levels (BALs) in HDID-1 mice. Tacrolimus reduced ethanol intake and BALs. Tacrolimus had no effect on water intake, but reduced saccharin intake. There was no effect of sirolimus, PEA, or secukinumab on ethanol intake or BALs. These results compare and contrast with previous work addressing these compounds or their targeted mechanisms of action on ethanol drinking, highlighting the importance of screening a wide range of models and genotypes to inform the role of neuroimmune signaling in AUDs.

Original languageEnglish (US)
JournalNeuroscience Insights
Volume15
DOIs
StatePublished - 2020

Keywords

  • Binge drinking
  • HDID-1
  • immune
  • pharmacotherapy

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Effects of Tacrolimus and Other Immune Targeting Compounds on Binge-Like Ethanol Drinking in High Drinking in the Dark Mice'. Together they form a unique fingerprint.

Cite this